Custom synthesis | Naphthyridine | Pyrimidine | Indoline |
New Melocules

439081-18-2 Afatinib

Afatinib is a drug approved for the first-line treatment of patients with distinct types of metastatic (EGFR mutation positive) non-small cell lung carcinoma (NSCLC), developed by Boehringer Ingelheim. It acts as an irreversible covalent inhibitor of the receptor tyrosine kinases epidermal growth factor receptor (EGFR) and erbB-2 (HER2).

439081-18-2 Afatinib
Afatinib 439081-18-2
Appearance:White powder
Cas No:439081-18-2
EINECS:NA
Formula:C24H25ClFN5O3
Molecular Weight:485.94
Melting Point:NA
Boiling Point:676.9°C
Flash Point: 363.1°C
Usage:antineoplastics
Testing Items
Standards:Enterprise
Appearance
White to off-white powder
Identification
should conform
Purity NLT98%

GMP for 439081-18-2 Afatinib is available, DMF for 439081-18-2 Afatinib is under preparation
 
Disclaimer:Those products (439081-18-2 Afatinib) patented are for lab analytical & research purposes only.